{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:48Z","timestamp":1740126468247,"version":"3.37.3"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Blood services are required to maintain repositories of frozen samples for confirmation of results and\/or retrospective testing. The Australian Red Cross Blood Service archives donor samples in plasma preparation tubes (PPTs). This study aims to evaluate the effect of freeze\u2010thawing and extended frozen storage on the ability to detect human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) using blood donation screening assays in samples stored in PPTs.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Whole blood was spiked with HIV\u2010, HCV\u2010, or HBV\u2010reactive plasma at high and low viral loads and stored in PPTs or as plasma aliquots. All samples were frozen and stored at not more than \u221230\u00b0C. At 0, 3, 6, 12, 18, and 36 months, samples were tested for HIV and HCV antibodies, HBV surface antigen, and viral nucleic acid. Additional samples were thawed and refrozen either once or twice before testing to simulate up to three freeze\u2010thaw cycles.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>All PPT and plasma aliquots retained appropriate viral reactivity, including those with multiple freeze\u2010thaw cycles, on both nucleic acid testing and serology platforms.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Frozen storage of biologicals in PPTs, as opposed to plasma aliquots, does not affect the ability to detect HIV, HCV, and HBV using viral nucleic acid or serology donation screening systems for up to 36 months. Freezing and thawing PPT samples did not impact the ability to detect these viruses. Our study demonstrates that PPTs appear to be an appropriate receptacle for frozen plasma sample archiving for up to 3 years.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.13372","type":"journal-article","created":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T22:43:28Z","timestamp":1444689808000},"page":"449-456","source":"Crossref","is-referenced-by-count":6,"title":["The impact on blood donor screening for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus using plasma from frozen\u2010thawed plasma preparation tubes"],"prefix":"10.1111","volume":"56","author":[{"given":"Kirsty M.","family":"Allison","sequence":"first","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service Brisbane"},{"name":"Manufacturing Australian Red Cross Blood Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M.","family":"Faddy","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service Brisbane"},{"name":"School of Medicine University of Queensland Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Margaritis","sequence":"additional","affiliation":[{"name":"Manufacturing Australian Red Cross Blood Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ismay","sequence":"additional","affiliation":[{"name":"Manufacturing Australian Red Cross Blood Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denese C.","family":"Marks","sequence":"additional","affiliation":[{"name":"Research and Development Australian Red Cross Blood Service Brisbane"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.01.002"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.01522"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.00453"},{"volume-title":"Use of anticoagulants in diagnostic laboratory investigations, Rev 2","year":"1999","key":"e_1_2_8_5_1"},{"key":"e_1_2_8_6_1","unstructured":"DupontI MercierB DurandF et al. Comparative evaluation of fresh and frozen serum and plasma for serological and NAT analysis. Paris: 7th European Congress of the International Society of Blood Transfusion;2001."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4635-4639.2005"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00083-10"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02034-09"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.6.1683-1686.1999"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02447-10"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03747.x"},{"key":"e_1_2_8_13_1","unstructured":"Therapeutic Goods Order No. 88 \u2010 Standards for donor selection testing and minimising infectious disease transmission via therapeutic goods that are human blood and blood components human tissues and human cellular therapy products. Therapeutic Goods ACT \u2010 section 10. Woden: TGA;1989."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00857.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973-6247.150944"},{"volume-title":"Guide to the preparation, use and quality assurance of blood components","year":"2008","key":"e_1_2_8_16_1"},{"volume-title":"Procleix Ultrio assay package insert \u2010 [501555EN Rev. A]","year":"2010","key":"e_1_2_8_17_1"},{"volume-title":"Procleix Ultrio Plus assay package insert \u2010 [504105 Rev. 1]","year":"2014","key":"e_1_2_8_18_1"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01761-08"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04215.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025899"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-0934(88)90146-2"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.13372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.13372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T07:41:36Z","timestamp":1697269296000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.13372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/trf.13372"],"URL":"https:\/\/doi.org\/10.1111\/trf.13372","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}